Yes. The BUPA study meant there was some reworking required in terms of the protein biomarkers and their synergy. They felt they were across it is my understanding and part of the $9m will be used to demonstrate the desired results. For the $11m EV, it seems a decent punt, but we know life science can be binary.
I guess your nearest peer listing in recent times would be BD1, which listed around the same price and was cheap enough to give some good speculative uplift into trials. Results were less than impressive in their case unfortunately.
